Athira Pharma Management
Management criteria checks 1/4
Athira Pharma's CEO is Mark Litton, appointed in Oct 2021, has a tenure of 2.58 years. total yearly compensation is $2.26M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth $323.25K. The average tenure of the management team and the board of directors is 1.3 years and 2.5 years respectively.
Key information
Mark Litton
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 25.9% |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$585k | -US$118m |
| Sep 30 2023 | n/a | n/a | -US$121m |
| Jun 30 2023 | n/a | n/a | -US$108m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$4m | US$543k | -US$96m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$450k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$46m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | n/a | n/a | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$204k | US$12k | -US$5m |
Compensation vs Market: Mark's total compensation ($USD2.26M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Litton (55 yo)
2.6yrs
Tenure
US$2,261,564
Compensation
Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of Athira Pharma, Inc. since July 2019 until October 18, 2021 and serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$2.26m | 0.43% $ 323.3k | |
| CFO & Chief Business Officer | less than a year | US$1.33m | 0.22% $ 165.1k | |
| Chief Development Officer & COO | 2.6yrs | US$2.03m | 0.035% $ 26.4k | |
| Chief Scientific Officer | 1.3yrs | US$135.32k | 0.21% $ 158.1k | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Corporate Secretary | 2.9yrs | US$2.71m | 0.090% $ 67.9k | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.3yrs
Average Tenure
56yo
Average Age
Experienced Management: ATHA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.6yrs | US$2.26m | 0.43% $ 323.3k | |
| Independent Director | 9.4yrs | US$95.89k | 0.38% $ 285.4k | |
| Independent Director | 2.3yrs | US$96.53k | 0.067% $ 50.8k | |
| Independent Chairwoman of the Board | 3.4yrs | US$124.68k | 0.16% $ 123.2k | |
| Independent Director | 4yrs | US$92.77k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 1.9yrs | US$1.29m | 0.24% $ 180.2k | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Independent Director | 3.2yrs | US$102.39k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$89.36k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$149.06k | 0.013% $ 9.9k | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data |
2.5yrs
Average Tenure
63yo
Average Age
Experienced Board: ATHA's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.